Novavax To Participate In Oxford University Study Comparing Mixed COVID-19 Vaccine

Novavax Inc. (NVAX) said Thursday that it will participate in a newly expanded Phase 2 clinical trial called "Comparing COVID-19 Vaccine Schedule Combinations - Stage 3" or Com-COV3. The study will be led by the University of Oxford and funded by the UK Vaccines Taskforce or VTF and the National Institute for Health Research or NIHR.

Novavax' recombinant nanoparticle COVID-19 vaccine candidate, NVX-CoV2373, is one of the three COVID-19 vaccines that will be studied in adolescents to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19.

The clinical trial will include at least 360 adolescents 12-16 years of age. Volunteers will receive an authorized vaccine as a first dose and then at least 8 weeks later will receive one of three different vaccines as a second dose.

The company noted that all participants will be randomly allocated at the time of the second dose to receive either a full dose or half dose of the same vaccine given for the first dose, a full dose of the Novavax vaccine or a half dose of a different authorized vaccine.

The research will compare the immune system responses from those who receive a heterologous regimen to those who receive a homologous regimen.

Under the protocol, participants will be followed for safety and immune responses. Results from the study are expected within a few months.

The company stated that the UK Medicines and Healthcare products Regulatory Agency and Joint Committee on Vaccination and Immunisation will formally assess the safety and efficacy of any new vaccination process before advising whether it is rolled out.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT